Becton Dickinson and Co (NYSE:BDX) Shares Sold by RMB Capital Management LLC

RMB Capital Management LLC decreased its holdings in shares of Becton Dickinson and Co (NYSE:BDX) by 0.1% during the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 64,291 shares of the medical instruments supplier’s stock after selling 47 shares during the quarter. RMB Capital Management LLC’s holdings in Becton Dickinson and were worth $14,772,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Ascent Wealth Partners LLC boosted its holdings in shares of Becton Dickinson and by 1.3% during the first quarter. Ascent Wealth Partners LLC now owns 30,782 shares of the medical instruments supplier’s stock worth $7,073,000 after purchasing an additional 389 shares during the last quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund boosted its holdings in Becton Dickinson and by 8.9% in the fourth quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 80,455 shares of the medical instruments supplier’s stock valued at $21,881,000 after acquiring an additional 6,600 shares during the last quarter. KBC Group NV boosted its holdings in Becton Dickinson and by 29.1% in the fourth quarter. KBC Group NV now owns 109,904 shares of the medical instruments supplier’s stock valued at $29,891,000 after acquiring an additional 24,750 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its holdings in Becton Dickinson and by 47.0% in the fourth quarter. Caisse DE Depot ET Placement DU Quebec now owns 35,344 shares of the medical instruments supplier’s stock valued at $9,613,000 after acquiring an additional 11,300 shares during the last quarter. Finally, Kidder Stephen W boosted its holdings in Becton Dickinson and by 12.0% in the first quarter. Kidder Stephen W now owns 17,270 shares of the medical instruments supplier’s stock valued at $3,968,000 after acquiring an additional 1,856 shares during the last quarter. Institutional investors and hedge funds own 86.79% of the company’s stock.

A number of brokerages recently weighed in on BDX. Morgan Stanley reduced their target price on Becton Dickinson and from $271.00 to $255.00 and set an “equal weight” rating on the stock in a report on Friday, March 27th. TheStreet cut Becton Dickinson and from a “b” rating to a “c+” rating in a report on Monday, March 9th. Piper Sandler raised their price objective on Becton Dickinson and from $286.00 to $296.00 and gave the company an “overweight” rating in a research report on Thursday, May 14th. Wells Fargo & Co reissued a “buy” rating on shares of Becton Dickinson and in a research report on Friday, May 8th. Finally, Cowen lowered Becton Dickinson and from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $306.00 to $275.00 in a research report on Thursday, February 6th. Nine analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $275.79.

Shares of NYSE BDX traded up $0.31 during midday trading on Friday, reaching $239.25. 11,783,270 shares of the company’s stock were exchanged, compared to its average volume of 1,932,654. Becton Dickinson and Co has a 52-week low of $197.75 and a 52-week high of $286.72. The stock has a market capitalization of $64.79 billion, a PE ratio of 72.06, a price-to-earnings-growth ratio of 2.57 and a beta of 0.95. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.66 and a current ratio of 0.98. The business’s fifty day moving average price is $253.35 and its two-hundred day moving average price is $255.35.

Becton Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, May 7th. The medical instruments supplier reported $2.55 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.32 by $0.23. Becton Dickinson and had a return on equity of 15.75% and a net margin of 6.10%. The business had revenue of $4.25 billion for the quarter, compared to analyst estimates of $4.10 billion. During the same period in the previous year, the company earned $2.59 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Analysts predict that Becton Dickinson and Co will post 10.5 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 1.32%. The ex-dividend date is Monday, June 8th. Becton Dickinson and’s payout ratio is 27.05%.

Becton Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

See Also: Dogs of the Dow

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).

Institutional Ownership by Quarter for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.